Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to 52.36%.

  • Karyopharm Therapeutics' EBIT Margin rose 500600.0% to 52.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 62.1%, marking a year-over-year increase of 201400.0%. This contributed to the annual value of 62.1% for FY2025, which is 201400.0% up from last year.
  • Karyopharm Therapeutics' EBIT Margin amounted to 52.36% in Q4 2025, which was up 500600.0% from 34.56% recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' EBIT Margin peaked at 37.19% during Q4 2021, and registered a low of 225.16% during Q1 2021.
  • Over the past 5 years, Karyopharm Therapeutics' median EBIT Margin value was 86.07% (recorded in 2022), while the average stood at 92.27%.
  • Within the past 5 years, the most significant YoY rise in Karyopharm Therapeutics' EBIT Margin was 1526100bps (2022), while the steepest drop was -1380500bps (2022).
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' EBIT Margin stood at 37.19% in 2021, then plummeted by -371bps to 100.86% in 2022, then fell by -11bps to 112.03% in 2023, then rose by 9bps to 102.42% in 2024, then soared by 49bps to 52.36% in 2025.
  • Its last three reported values are 52.36% in Q4 2025, 34.56% for Q3 2025, and 64.3% during Q2 2025.